Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Leuk Res Rep. 2022 Apr 13:17:100314. doi: 10.1016/j.lrr.2022.100314. eCollection 2022.

Authors

Thiti Asawapanumas^{1

2}, Chantiya Chanswangphuwana^{1

2}, Phandee Watanaboonyongcharoen³, Ponlapat Rojnuckarin^{1

2}, Udomsak Bunworasate^{1

2}

Affiliations

¹ Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
² Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, Thailand.
³ Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University and Transfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

No abstract available

Keywords: Daratumumab; Major ABO-mismatched; Pure red cell aplasia.

Publication types

Case Reports